Endovascular Therapy or Medical Management Alone for Isolated Posterior Cerebral Artery Occlusion: A Multicenter Study.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
04 2023
Historique:
medline: 29 3 2023
pubmed: 3 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

Whether endovascular therapy (EVT) added on best medical management (BMM), as compared to BMM alone, is beneficial in acute ischemic stroke with isolated posterior cerebral artery occlusion is unknown. We conducted a multicenter international observational study of consecutive stroke patients admitted within 6 hours from symptoms onset in 26 stroke centers with isolated occlusion of the first (P1) or second (P2) segment of the posterior cerebral artery and treated either with BMM+EVT or BMM alone. Propensity score with inverse probability of treatment weighting was used to account for baseline between-groups differences. The primary outcome was 3-month good functional outcome (modified Rankin Scale [mRS] score 0-2 or return to baseline modified Rankin Scale). Secondary outcomes were 3-month excellent recovery (modified Rankin Scale score 0-1), symptomatic intracranial hemorrhage, and early neurological deterioration. Overall, 752 patients were included (167 and 585 patients in the BMM+EVT and BMM alone groups, respectively). Median age was 74 (interquartile range, 63-82) years, 329 (44%) patients were female, median National Institutes of Health Stroke Scale was 6 (interquartile range 4-10), and occlusion site was P1 in 188 (25%) and P2 in 564 (75%) patients. Baseline clinical and radiological data were similar between the 2 groups following propensity score weighting. EVT was associated with a trend towards lower odds of good functional outcome (odds ratio, 0.81 [95% CI, 0.66-1.01]; In this observational study of patients with proximal posterior cerebral artery occlusion, EVT was not associated with good or excellent functional outcome as compared to BMM alone. However, EVT was associated with higher rates of symptomatic intracranial hemorrhage and early neurological deterioration. EVT should not be routinely recommended in this population, but randomization into a clinical trial is highly warranted.

Sections du résumé

BACKGROUND
Whether endovascular therapy (EVT) added on best medical management (BMM), as compared to BMM alone, is beneficial in acute ischemic stroke with isolated posterior cerebral artery occlusion is unknown.
METHODS
We conducted a multicenter international observational study of consecutive stroke patients admitted within 6 hours from symptoms onset in 26 stroke centers with isolated occlusion of the first (P1) or second (P2) segment of the posterior cerebral artery and treated either with BMM+EVT or BMM alone. Propensity score with inverse probability of treatment weighting was used to account for baseline between-groups differences. The primary outcome was 3-month good functional outcome (modified Rankin Scale [mRS] score 0-2 or return to baseline modified Rankin Scale). Secondary outcomes were 3-month excellent recovery (modified Rankin Scale score 0-1), symptomatic intracranial hemorrhage, and early neurological deterioration.
RESULTS
Overall, 752 patients were included (167 and 585 patients in the BMM+EVT and BMM alone groups, respectively). Median age was 74 (interquartile range, 63-82) years, 329 (44%) patients were female, median National Institutes of Health Stroke Scale was 6 (interquartile range 4-10), and occlusion site was P1 in 188 (25%) and P2 in 564 (75%) patients. Baseline clinical and radiological data were similar between the 2 groups following propensity score weighting. EVT was associated with a trend towards lower odds of good functional outcome (odds ratio, 0.81 [95% CI, 0.66-1.01];
CONCLUSIONS
In this observational study of patients with proximal posterior cerebral artery occlusion, EVT was not associated with good or excellent functional outcome as compared to BMM alone. However, EVT was associated with higher rates of symptomatic intracranial hemorrhage and early neurological deterioration. EVT should not be routinely recommended in this population, but randomization into a clinical trial is highly warranted.

Identifiants

pubmed: 36729389
doi: 10.1161/STROKEAHA.122.042283
doi:

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

928-937

Investigateurs

Kateryna Antonenko (K)
Caroline Arquizan (C)
Lynda Benammar (L)
Claire Boutet (C)
Frédéric Clarençon (F)
Pierre-Olivier Comby (PO)
Hubert Desal (H)
Olivier Detante (O)
François Eugene (F)
Emmanuel Gerardin (E)
Benjamin Gory (B)
Stéphane Kremer (S)
Sylvain Ledure (S)
Mathieu Krug (M)
Bertrand Lapergue (B)
Philippe Niclot (P)
Christophe Magni (C)
Michael Obadia (M)
Canan Ozsancak (C)
Fernando Pico (F)
Sara Pilgram-Pastor (S)
Raoul Pop (R)
Sébastien Richard (S)
Charlotte Rosso (C)
Julien Savatovsky (J)
Solène Moulin (S)
Clément Tracol (C)
Martin Zbinden (M)

Auteurs

Candice Sabben (C)

Neurology Department (C.S., P.S.), Rothschild Foundation Hospital, Paris, France.

Frédérique Charbonneau (F)

Neuroradiology Department (F.C.), Rothschild Foundation Hospital, Paris, France.

François Delvoye (F)

Interventional Neuroradiology Department (F.D., M.M.), Rothschild Foundation Hospital, Paris, France.

Davide Strambo (D)

Stroke Center, Neurology Service (D.S., P.M.), Lausanne University Hospital and University of Lausanne, Switzerland.

Mirjam R Heldner (MR)

Department of Neurology, University Hospital and University of Bern, Switzerland (M.R.H.).

Elodie Ong (E)

Stroke Department, Hospices Civils de Lyon, France (E.O.).

Adrien Ter Schiphorst (A)

Neurology Department, CHRU Gui de Chauliac, Montpellier, France (A.T.S.).

Hilde Henon (H)

Neurology department, Stroke Center, University of Lille, Inserm U1171, CHU Lille, LilNCog - Lille Neuroscience & Cognition, France (H.H.).

Wagih Ben Hassen (W)

Neuroradiology Department, GHU Paris Psychiatrie and Neurosciences, Paris, France (W.B.H.).

Thomas Agasse-Lafont (T)

Neurology Department, CHU Rennes, France (T.A.-L.).

Loïc Legris (L)

Neurology Department, Stroke Unit, Grenoble Alpes University Hospital, University of Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France (L.L.).

Igor Sibon (I)

Stroke Unit, Bordeaux University Hospital, France (I.S.).

Valérie Wolff (V)

Stroke Unit, Strasbourg University Hospital, France (V.W.).

Denis Sablot (D)

Neurology Department, CH Perpignan, France (D.S.).

Mahmoud Elhorany (M)

Interventional Neuroradiology Department, Pitié-Salpétrière Hospital, Paris, France (M.E.).
Neurology Department, Faculty of Medicine, Tanta University, Egypt (M.E.).

Cécile Preterre (C)

Neurology Department, CHU Nantes, France (C.P.).

Nour Nehme (N)

Neurology Department, André Mignot Hospital, Versailles, France (N.N.).

Sébastien Soize (S)

Neuroradiology Department, CHU Reims, France (S.S.).

David Weisenburger-Lile (D)

Neurology Department, Foch Hospital, Suresnes, France (D.W.-L.).

Aude Triquenot-Bagan (A)

Neurology Department, Rouen University Hospital, F-76000, Rouen, France (A.T.-B.).

Gioia Mione (G)

Neurology Department, University Hospital of Nancy, France (G.M.).

Andreea Aignatoaie (A)

Neurology Department, CHR Orléans, France (A.A.).

Jérémie Papassin (J)

Neurology Department, CH Metropole Savoie, Chambery, France (J.P.).

Roxana Poll (R)

Neurology Department, Rene Dubois Hospital, Pontoise, France (R.P.).

Yannick Béjot (Y)

Neurology Department, CHU Dijon, France (Y.B.).

Emmanuel Carrera (E)

Neurology Department, Geneve University Hospital, Switzerland (E.C.).

Pierre Garnier (P)

Neurology Department, Stroke Unit, CHU St Etienne, France (P.G.).

Patrik Michel (P)

Stroke Center, Neurology Service (D.S., P.M.), Lausanne University Hospital and University of Lausanne, Switzerland.

Guillaume Saliou (G)

Diagnostic and Interventional Radiology Department (G.S.), Lausanne University Hospital and University of Lausanne, Switzerland.

Pasquale Mordasini (P)

Netzwerk Radiology, Kantonsspital St. Gallen, Switzerland (P.M.).

Yves Berthezene (Y)

Neuroradiology Department, Hospices Civils de Lyon, France (Y.B.).

Vincent Costalat (V)

Neuroradiology Department, CHRU Gui de Chauliac, Montpellier, France (V.C.).

Nicolas Bricout (N)

Interventional Neuroradiology Department, CHU Lille, France (N.B.).

Gregory W Albers (GW)

Stanford Stroke Center, Stanford University, Palo Alto, CA (G.W.A., P.S.).

Mikael Mazighi (M)

Interventional Neuroradiology Department (F.D., M.M.), Rothschild Foundation Hospital, Paris, France.
Neurology Department, Lariboisière Hospital, APHP Nord, INSERM 1148, Université Paris Cité, Paris, France (M.M.).
FHU Neurovasc (M.M., G.T.).

Guillaume Turc (G)

FHU Neurovasc (M.M., G.T.).
Neurology Department, GHU Paris Psychiatrie and Neurosciences, Paris, France (G.T.).
Institut de Psychiatrie et Neurosciences de Paris, INSERM UMR_S1266, Université Paris Cité, France (G.T., P.S.).

Pierre Seners (P)

Neurology Department (C.S., P.S.), Rothschild Foundation Hospital, Paris, France.
Stanford Stroke Center, Stanford University, Palo Alto, CA (G.W.A., P.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH